Primary NTRK-rearranged spindle cell sarcoma of the colon with ETV6-NTRK3 fusion.

BMJ Case RepSep 17, 2026 (epub)

Yuan-Yin Zheng, Ying-Yu Mao, Mao-Hua Lin et al.

✦ AI-curated · Sources linked

Case in brief

A man in his late 30s presented with abdominal pain, leading to a CT scan that revealed a large transmural tumor in the colon. The multidisciplinary team opted for immediate surgery without preoperative colonoscopy. Histopathology and next-generation sequencing confirmed a spindle cell neoplasm with an ETV6-NTRK3 fusion. Following a complete resection, the patient declined adjuvant chemotherapy and remained recurrence-free at 8 months.

What made this case unusual

The case highlights an unexpected strong CD31 positivity in the tumor, which is not typically associated with spindle cell sarcomas and requires further validation.

Diagnostic / clinical pearl

Molecular confirmation of NTRK fusions is crucial for accurate diagnosis and potential eligibility for targeted therapies in spindle cell sarcomas.

Why it matters

This case contributes to the understanding of gastrointestinal NTRK-rearranged sarcomas, emphasizing the need for awareness of atypical immunohistochemical findings.

Source

Published in BMJ Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.